<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Emulate — Prospect Detail</title>
  <link rel="stylesheet" href="styles.css">
</head>
<body>
<header class="site-header"><h1>Prospect Detail</h1></header>
<div class="container">
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
  <div class="detail-header">
    <span class="badge health" style="font-size:.8rem;">Digital Health</span>
    <h1>51. Emulate</h1>
    <p class="meta">Organs-on-Chips Technology</p>
  </div>
  <div class="section"><h3>1. Startup Name</h3><p><strong>Emulate</strong></p></div>
  <div class="section"><h3>2. Founder Contact</h3><p><strong>Wyss Institute Team</strong></p><p>Wyss Institute for Biologically Inspired Engineering at Harvard</p><p>Founded by Don Ingber, MD PhD (Wyss Institute Founding Director) and team</p></div>
  <div class="section"><h3>3. Product Overview</h3><p>Emulate's Organs-on-Chips technology recreates human biology to transform how scientists research diseases and develop drugs. The platform uses microfluidic devices lined with human cells that mimic the physiology of human organs, enabling more accurate predictions of drug efficacy and toxicity than traditional animal testing.</p></div>
  <div class="section"><h3>4. Funding Stage</h3><p><strong>Series E</strong> — Raised $225M+ in total funding from investors including Northpond Ventures and others.</p></div>
  <div class="section"><h3>5. How I Found the Company</h3><p>Discovered through Wyss Institute spinout company portfolio and biotechnology innovation tracking.</p></div>
  <div class="strengths-weaknesses">
    <div class="section"><h3>Strengths</h3><ul><li><strong>Revolutionary technology:</strong> Organs-on-Chips can reduce drug development costs and timelines significantly.</li><li><strong>Scientific credibility:</strong> Wyss Institute backing provides unparalleled research validation.</li></ul></div>
    <div class="section"><h3>Weaknesses</h3><ul><li><strong>Long sales cycles:</strong> Pharma adoption of new methodologies takes years.</li><li><strong>Regulatory acceptance:</strong> FDA and EMA still developing frameworks for organ-chip data.</li></ul></div>
  </div>
  <div class="section"><h3>7. Five Questions for the Team</h3><ol class="questions-list"><li>How many pharmaceutical companies are actively using your platform?</li><li>What organs have the highest commercial demand for chip development?</li><li>How do you validate that organ-chip results translate to human outcomes?</li><li>What is your regulatory strategy for replacing animal testing requirements?</li><li>How do you compete with other organ-on-chip companies like Tissuse or CN Bio?</li></ol></div>
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
</div>
</body>
</html>
